title: Sirolimus-eluting stent vs. everolimus-eluting stent for coronary intervention in patients on chronic hemodialysis.
abstract: BACKGROUND
  Even in the drug-eluting stent era, adverse cardiac events, including restenosis after percutaneous coronary intervention (PCI), have been more frequently seen in patients on hemodialysis (HD) than in non-HD patients. The objective of this study was to compare the sirolimus-eluting stent (SES) and everolimus-eluting stent (EES) for prevention of adverse cardiac events, including restenosis, in HD patients.
  
  
  RESULTS
  A total of 100 consecutive patients on HD who underwent PCI were enrolled and randomly assigned to receive SES or EES. Although there was no difference between the 2 groups in baseline patient and lesion characteristics, the angiographic restenosis rate at 8-month follow-up was 21.2% in the SES group and 8.7% in the EES group (P = 0.041). Significant differences were also seen in % diameter stenosis (%DS), minimal lumen diameter, and late lumen loss at 8-month follow-up (P = 0.0024, P = 0.0040, and P = 0.033, respectively). During the 1-year follow-up, major adverse cardiac events occurred in 11 (22.0%) patients in the SES group and in 5 (10.0%) patients in the EES group (P = 0.10).
  
  
  CONCLUSIONS
  The use of EES was as safe as that of SES. Moreover, EES significantly prevented restenosis in patients on maintenance HD compared with SES.
authors: Cardiovascular Center, Nagoya Kyoritsu Hospital, Nagoya, Japan.
authors: Takashi
authors: T
authors: Sakakibara
authors: Hideki
authors: H
authors: Ishii
authors: Takanobu
authors: T
authors: Toriyama
authors: Toru
authors: T
authors: Aoyama
authors: Hiroshi
authors: H
authors: Takahashi
authors: Daisuke
authors: D
authors: Kamoi
authors: Yoshihiro
authors: Y
authors: Kawamura
authors: Kazuhiro
authors: K
authors: Kawashima
authors: Kohei
authors: K
authors: Yoneda
authors: Tetsuya
authors: T
authors: Amano
authors: Miho
authors: M
authors: Tanaka
authors: Daiji
authors: D
authors: Yoshikawa
authors: Mutsuharu
authors: M
authors: Hayashi
authors: Tatsuaki
authors: T
authors: Matsubara
authors: Toyoaki
authors: T
authors: Murohara
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D003327:Coronary Disease / Q000150:complications / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus